These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 37885090)

  • 1. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
    Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
    Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-associated genes (CAGs) contribute to the prognosis prediction and potential therapeutic targets in hepatocellular carcinoma.
    Shi X; Shi D; Yin Y; Wu Y; Chen W; Yu Y; Wang X
    Cell Signal; 2024 May; 117():111072. PubMed ID: 38307306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
    Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
    Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of prognosis, immune infiltration, and personalized treatment of hepatocellular carcinoma by analysis of cuproptosis-related long noncoding RNAs and verification
    Li S; Zhu Z; Lu J; Cao W; Song F; Xiao C; Zhang P; He Z; Weng J; Xu J
    Front Oncol; 2023; 13():1159126. PubMed ID: 37746284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct cuproptosis patterns in hepatocellular carcinoma patients correlate with unique immune microenvironment characteristics and cell-cell communication, contributing to varied overall survival outcomes.
    Wang Y; Mang X; Guo X; Pu J
    Front Immunol; 2024; 15():1379690. PubMed ID: 38868777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
    Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
    Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 12. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
    Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
    Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
    Front Genet; 2023; 14():1094793. PubMed ID: 36891150
    [No Abstract]   [Full Text] [Related]  

  • 15. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
    Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
    Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.
    Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S
    Front Immunol; 2022; 13():945516. PubMed ID: 36248857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of the cuproptosis-related molecular subtypes and an immunotherapy prognostic model in hepatocellular carcinoma.
    Zhang L; Xu J; Chu X; Zhang H; Yao X; Zhang J; Guo Y
    BMC Bioinformatics; 2022 Nov; 23(1):485. PubMed ID: 36384423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC.
    Wang Y; Zhang Y; Wang L; Zhang N; Xu W; Zhou J; Zhao Y; Zhu W; Zhang T; Wang L
    Hepatol Int; 2022 Dec; 16(6):1435-1447. PubMed ID: 36065073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.